YourChoice Therapeutics
YourChoice Therapeutics is developing YCT-529, the first oral contraceptive designed for men, now in Phase 2 clinical trials. This non-hormonal daily pill selectively blocks retinoic acid receptor-alpha (RAR-alpha), a receptor essential for sperm production, with preclinical studies showing the effect reverses after stopping treatment. The company sponsors and collaborates on clinical studies evaluating safety, tolerability, and pharmacokinetics of the investigational agent.
- Drug Discovery & Therapeutics
- Healthcare Technology
- Biotechnology
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Women have had access to oral contraceptives for over 60 years, while men have only two options: condoms or vasectomy. This limited choice places the burden of contraception disproportionately on women and leaves men without a reversible, non-surgical alternative.
Solution
YourChoice Therapeutics is developing YCT-529, the first oral contraceptive designed for men, now in Phase 2 clinical trials. YCT-529 is a non-hormonal daily pill that selectively blocks retinoic acid receptor-alpha (RAR-alpha), a receptor essential for sperm production. In preclinical studies, the effect on sperm production reversed after stopping treatment, suggesting a reversible contraceptive option. The company sponsors and collaborates on clinical studies evaluating safety, tolerability, and pharmacokinetics of the investigational agent.
Target Audience
Primary customers are men seeking reversible, non-hormonal contraceptive options, as well as healthcare providers and family planning organizations looking to expand male contraception choices.
Features
- Non-hormonal mechanism targeting retinoic acid receptor-alpha (RAR-alpha), a receptor essential for spermatogenesis
- Oral daily pill formulation designed for self-administration
- Reversible contraceptive effect demonstrated in preclinical studies after treatment cessation
- Currently in Phase 2 clinical trials evaluating safety, tolerability, and pharmacokinetics
- Registered on ClinicalTrials.gov with active clinical development program